The Candidate Sample Clauses

The "The Candidate" clause defines who is considered the candidate within the context of the agreement, typically identifying the individual being considered for employment or engagement. This clause may specify the candidate's name, role, or other identifying details, and clarify their status in relation to the parties involved. By clearly designating the candidate, the clause ensures there is no ambiguity about whom the agreement pertains to, thereby preventing misunderstandings or disputes regarding the subject of the contract.
POPULAR SAMPLE Copied 1 times
The Candidate. 33.4.1 (a) No later than September 15 of the Academic Year in which an application for renewal, promotion or tenure is to be considered, the candidate (only faculty Members holding probationary tenure-track or tenured appointments are eligible to make an application under this Article) shall forward to the Office of the Vice- President, Academic and ▇▇▇▇▇▇▇, an electronic copy (in PDF format) of the application, and shall at the same time advise in writing the ▇▇▇▇(s) of the School(s) concerned that such application has been submitted. The Vice- President, Academic and ▇▇▇▇▇▇▇, will ensure access to the submitted documents will be provided to the Department, the ▇▇▇▇ and members of PP&T Committee. It is the responsibility of the candidate to ensure that her/his application contains only complete and accurate information. Failure by the potential candidate to make the required application for renewal (see clause 33.11) or tenure (see clause 33.12) shall conclusively be deemed a resignation of her/his employment at the University effective the June 30 immediately following.
View SourceView Similar (5)
The Candidate. (a) No member will normally be eligible to apply for promotion to Senior Instructor (I or II) without three (3) years of teaching at the Instructor level or equivalent at CBU. No member will normally be eligible to apply for promotion to Senior Lab Technologist without three (3) years of teaching at the Lab Technologist level or equivalent at CBU. Consideration may be given to recent past relevant teaching in a comparable full-time position outside of CBU if the candidate provides substantiating materials such as course syllabi, teaching evaluations, etc., to the ▇▇▇▇ at the time of hiring. The ▇▇▇▇, in consultation with the Human Resources Department, will determine if such past teaching experience will be eligible for consideration should the Member apply for promotion at a future date. However, no member will be eligible to apply for promotion without a minimum of two (2) years of teaching at CBU. The required three (3) years of teaching experience must be completed at the time the application is made.
View SourceView Similar (3)
The Candidate. Describe the candidate by name, address and qualifications. Make reference to any academic records and experience in surveying contained in attachments.
View SourceView Similar (2)
The Candidate. 33.4.1 No later than October 1 of the Academic Year in which an application for renewal, promotion or tenure is to be considered, the candidate (only faculty Members holding probationary tenure-track or tenured appointments are eligible to make an application under this Article) shall forward to the Chair of the Committee, the Chair of her/his Department(s), and to the office of the Director, Human Resources, a copy of the application, and shall at the same time advise in writing the ▇▇▇▇(s) of the School(s) concerned that such application has been submitted. It is the responsibility of the candidate to ensure that her/his application contains only complete and accurate information. Failure by the potential candidate to make the required application for renewal (see clause 33.11) or tenure (see clause 33.12) shall conclusively be deemed a resignation of her/his employment at the University effective the June 30 immediately following. In special circumstances, such as very serious illness, adoption or birth of a child, or in other situations where the candidate has been on approved leave of absence or is scheduled to take leave of absence, consideration will be given to relieving against strict compliance with the required application deadlines and mutually agreeable alternative dates established including the date for final decision on tenure. By no later than May 30 of the year preceding the Academic Year in which mandatory consideration for renewal or tenure is to occur, the Office of the Director of Human Resources will notify in writing each Member who is eligible for such consideration. No member will be eligible to be granted tenure if completion of a doctoral degree is a condition of employment as stated in his/her letter of appointment and if he/she has not successfully completed the doctoral degree. The member may request a deferral and shall submit a complete application under Article 33. The Committee will consider whether or not to recommend a deferral in accordance with provisions related to deferral under Article 33. 33.4.1.1 It is the responsibility of the candidate to provide complete and accurate documentary evidence as specified in 33.4.1.2. 33.4.1.2 The candidate shall provide the following documents with his/her application: (a) an up-to-date curriculum vitae; (b) a statement of his/her accomplishments and objectives in teaching, research/scholarly/creative activities, and service; (c) a list of university level courses she/he is teachi...
View Source
The Candidate. It shall be the responsibility of the candidate to maintain a documented record of their professional development, growth, and accomplishments and to submit the same to their departmental members and chairperson. (All references to “department” in this Article shall be understood to refer to the department into which the candidate was appointed or transferred following the procedures for such appointment or transfer specified in this Agreement.) This record shall include an updated vita covering all three (3) relevant areas (teaching, scholarly activity, and value); the candidate’s statement; a copy of the departmental criteria; evidence of scholarly activity; appropriate evaluation of teaching effectiveness (including but not limited to evaluation from departmental peers); and evidence of value to department, college/school, and University. In addition, the candidate shall supply copies of the Promotion and Tenure Committee’s recommendation(s) in their most recent previous application for promotion and/or tenure. The burden of demonstrating that this record is deserving of either promotion or tenure rests with the candidate.
View Source
The Candidate. A candidate to professional recognition can be any civil engineer that is recognized as such, in his own ECCE country.
View Source
The Candidate. (a) No member will normally be eligible to apply for promotion to Senior Instructor (I or II) without three (3) years of teaching at the Instructor level or equivalent at CBU. No member will normally be eligible to apply for promotion to Senior Lab Technologist without three (3) years of teaching at the Lab Technologist level or equivalent at CBU.
View Source

Related to The Candidate

  • Candidates The Superintendent or designee shall invite all current candidates for the office of Board member to attend:

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.